News

Sentinel Oncology receive Innovate UK grant to study feasibility of drug in the treatment of Alzheimer's disease

Sentinel Oncology is pleased to announce a recent award from Innovate UK

The recently awarded grant will help fund studies to investigate the feasibility of a Sentinel Oncology drug for the treatment of Alzeimer's disease. The award of over £135,000 will help fund the complex studies necessary to identify whether SOL784 is suitable for use in this complex CNS disorder. Bob Boyle, CEO of Sentinel Oncology said “with this additional funding from Innovate UK Sentinel Oncology will be able to develop an existing drug candidate into an exciting new therapeutic area."

About Sentinel Oncology Limited

Sentinel Oncology was founded in 2005 in Cambridge, UK and is a drug discovery company dedicated to the development and commercialisation of new therapeutics to treat cancer patients for whom there is currently an unmet medical need.

The Sentinel Oncology portfolio includes a lead programme that has been licensed to Cascadian Inc. and a second programme which is at the candidate drug phase. We are further developing a suite of novel small molecules designed to enhance therapeutic index by delivering the effects of drugs directly to the tumour.

Sentinel oncology is a fully integrated drug discovery company seeking to develop high quality drug candidates for partnering with the biotechnology and pharmaceutical industry. Our strategy relies on seeking partners and collaborators to maximise the value of our programmes.

About Innovate UK

Innovate UK is the UK’s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy.

For further information visit www.innovateuk.gov.uk

About the Biomedical Catalyst

The Biomedical Catalyst, announced by Prime Minister David Cameron in December 2011, is a £180 million programme of public funding designed to deliver growth to the UK life sciences sector. Delivered jointly by the Medical Research Council and the Technology Strategy Board, the Biomedical Catalyst provides responsive and effective support for the best life science opportunities arising in the UK.

Back to news list